Search for a trial

Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma.

To determine the best treatment for anaplastich oligodendroglial tumors with combined 1p/19q loss, and to determine the optimal treatment with respect to the maintenance of a maximal neurological and cognitive functioning.

ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients - A Groupwide Phase III Study

The goal of this study is to determine whether radiosensitization with carboplatin or the addition of Isotretinoin to maintenance therapy improves cure rates for children with other than average risk medulloblastoma/PNET.

Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.

PRIMARY OBJECTIVESthe assessment if survival in grade III glioma without combined 1p/19q loss is improved by - daily temozolomide chemotherapy during radiotherapy - the administration of temozolomide after the end of radiotherapy SECONDARY…

Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma

Assessment whether the addition of bevacizumab to lomustine improves overall survival in patients with recurrent glioblastoma

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with newly Diagnosed, Surgically Resected, EGFRvlll-positive Glioblastoma

The primary objective of the study is to confirm that the addition of rindopepimut?GM-CSF to adjuvant temozolomide improves overall survival in patients with newly diagnosed EGFRvIII positive glioblastoma who have undergone gross-total resection.

ACNS 0331: a study evaluating limited target volume boost irradiation and reduced dose craniospinal radiotherapy (18.00 Gy) and chemotherapy in children with newly diagnosed standard risk medulloblastoma: a phase III double randomized trial.

The aim of the study is to assess if a dose reduction of craniospinal irradiation in children with a medulloblastoma does not reduce event free survival (EFS) or overall survival (OS). Furthermore it will be assessed if a field reduction (only tumor…

A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION
VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED
GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS

To investigate if concomitant and adjuvant temozolomide chemotherapy improves survival in elderly patients that are managed with a short course of radiotherapy.

Phase III trial comparing conventional adjuvant Temozolomide with dose-intensive Temozolomide in patients with newly diagnosed glioblastoma

To determine if dose-intensifying the adjuvant temozolomide component of the chemoradiation treatment enhances treatment efficacy as measured by overall survival.

A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Subjects to Compare the Efficacy of AZD2171 [RECENTIN] Monotherapy and the Combination of AZD2171 with Lomustine to the Efficacy of Lomustine Alone

The Primary Objective of the study is to dettermine the relative efficacy of AZD2171 [RECENTIN] (both monotherapy or in combination with oral lomustine) compared to oral lomustine alone by assessment of progression free survival (PFS) as assessed by…

AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION
PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB
STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE
POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT

The objective of the study is to provide access to sunitinib treatment for patients who have completed a prior sunitinib study and are judged by the investigator to have the potential to benefit from sunitinib treatment. During this study the…

The effect of modafinil on fatigue, cognition and functional connectivity in low-grade glioma patients: a double-blind randomized trial.

(1) investigating the influence of modafinil on fatigue, cognitive functioning, and quality of life of LGG patients, (2) assessing the correlation between (changes in) fatigue, cognition, and quality of life on the one hand, and functional…

Glioblastoma, Optimizing Logistics and Dose (GOLD).

To test whether extremely hypofractionated radiotherapy (6 x 6 Gy) is non-inferior to standard radiotherapy (30 x 2 Gy) in terms of overall survival in patients with newly diagnosed GBM. Secondary objectives are to establish and compare health…

A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma- MIRAGE

The primary objective of this study is to compare overall survival (OS) in patients receiving Marizomib in combination with standard treatment (TMZ with concomitant RT, followed by TMZ maintenance therapy: TMZ/RT*TMZ) with patients receiving…

AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB - LR and PNET 5 MB - WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION AND REGISTRY FOR MB OCCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION

This study has been transitioned to CTIS with ID 2024-513724-42-00 check the CTIS register for the current data. PNET 5 MB-LR: Primary objective:-to confirm that the 3-year Event-Free Survival (EFS) rate in children and adolescents with standard-…

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS >=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

This study has been transitioned to CTIS with ID 2023-507933-12-00 check the CTIS register for the current data. MAIN OBJECTIVES:- To compare the efficacy of Dato-DXd in combination with pembrolizumab versus pembrolizumab alone, as measured by…

AN INTERNATIONAL PROSPECTIVE TRIAL ON HIGHRISK MEDULLOBLASTOMA IN PATIENTS OLDER THAN 3 YEARS

This study has been transitioned to CTIS with ID 2024-510578-25-00 check the CTIS register for the current data. Primary objectives:- To evaluate whether the outcome in children, young people and adults with HR-MB is improved over standard therapy i…

International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years.

Primary objective:-To confirm that the Event-Free Survival (EFS) in patients &gt;= 3 years of age with WHO grade IV/CNS WHO grade 4 and WHO grade III/CNS WHOgrade 3 diffuse high grade gliomas as well as diffuse high grade gliomas without a…

MR-guided LITT therapy in patients with primary irresectable glioblastoma: a multicenter randomized controlled trial

To prospectively evaluate the (cost)-effectiveness of LITT plus chemoradiation therapy (CRT) vs. CRT alone in patients with primary irresectable glioblastoma (GBM).

A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

This study has been transitioned to CTIS with ID 2024-510742-13-00 check the CTIS register for the current data. The primary objective is to compare the objective response rate (ORR) assessed per Response Assessment in Neuro Oncology for low-grade…

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of AG-881 in subjects with residual or recurrent grade 2 glioma with and IDH1 or IDH2 mutation

This study has been transitioned to CTIS with ID 2024-512961-15-00 check the CTIS register for the current data. Primary:• The primary objective of the study is to demonstrate the efficacy of vorasidenib based on radiographic progression-free…